ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
Intern Med J
; 53(12): 2319-2329, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-38014511
ABSTRACT
This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transplante de Células-Tronco Hematopoéticas
/
Síndrome de Bronquiolite Obliterante
/
Doença Enxerto-Hospedeiro
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article